The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.

By U. Ballehaninna, R. Chamberlain. Journal of Gastrointestinal Oncology, 2012

804 citations recorded by the source corpus.

Subfields: Biotechnology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/deba7736855f97f8611568921e5f78029d701167

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Richard D. Cummings
2. T. Ju
3. S. Stowell

Citations in the corpus

• Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies (2020, background): “, pancreatitis) or other gastrointestinal diseases (esophageal, gastric or biliary cancers) [85].”
• Protein Glycosylation in Cancer (2015, background): “Its sensitivity and specificity as a serum biomarker for pancreatic cancer are 79–81% and 82–90%, respectively (106).”